Photo of Filippo Montemurro taken from www.irccs.com
Jan 24, 2025, 15:03
Filippo Montemurro: Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
Filippo Montemurro, Senior Medical Director at F. Hoffmann La Roche, shared a post on LinkedIn:
“I am proud to share the publication of my recent work with the outstanding Gruppo Italiano Mammella (GIM). Describing attrition in metastatic cancers is valuable for oncologists because it helps address a critical clinical question: “If this patient progresses on the current treatment, what are the chances she/he will be able to receive subsequent therapy?”
Understanding attrition has several practical benefits that we address in this paper. Thanks to co-workers and in particular to Eva Blondeaux for her fantastic competence and committment.”
Authors: Eva Blondeaux et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 16:56
Feb 25, 2025, 15:10
Feb 25, 2025, 14:12
Feb 25, 2025, 14:04
Feb 25, 2025, 13:56
Feb 25, 2025, 13:46
Feb 25, 2025, 13:38